The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer

Seminars in Cell and Developmental Biology

Volumn 20, Issue 2, 2009, Pages 164-174

  Pruessmeyer, Jessica ^a   Ludwig, Andreas ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Metalloproteinase; Migration; Neuroprotection; Proliferation; Shedding

Indexed keywords

ADAM PROTEIN; ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CD30 ANTIGEN; CD40 LIGAND; CELL ADHESION MOLECULE; CXCL1 CHEMOKINE; CXCL16 CHEMOKINE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS LIGAND; GAMMA SECRETASE; GROWTH FACTOR; HERMES ANTIGEN; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JUNCTIONAL ADHESION MOLECULE A; L SELECTIN; NERVE CELL ADHESION MOLECULE; NOTCH RECEPTOR; PRION PROTEIN; PROTEIN ADAM10; PROTEIN ADAM17; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN;

ALZHEIMER DISEASE; BRAIN DISEASE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; COLON CARCINOMA; COLORECTAL CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; INFLAMMATION; KIDNEY CARCINOMA; LEUKOCYTE; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NEOPLASM; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PANCREAS ADENOCARCINOMA; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

EID: 63649105591     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2008.09.005     Document Type: Review

References (154)

1. Hartmann D., de Strooper B., Serneels L., Craessaerts K., Herreman A., Annaert W., et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 11 (2002) 2615-2624
2. Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnarborg S.W., Lee D.C., et al. An essential role for ectodomain shedding in mammalian development. Science 282 (1998) 1281-1284
3. Reiss K., Ludwig A., and Saftig P. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol Ther 111 (2006) 985-1006
4. Garton K.J., Gough P.J., and Raines E.W. Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J Leukoc Biol 79 (2006) 1105-1116
5. Blobel C.P. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 6 (2005) 32-43
6. Yang P., Baker K.A., and Hagg T. The ADAMs family: coordinators of nervous system development, plasticity and repair. Prog Neurobiol 79 (2006) 73-94
7. Moss M.L., Stoeck A., Yan W., and Dempsey P.J. ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol 9 (2008) 2-8
8. Black R.A., Doedens J.R., Mahimkar R., Johnson R., Guo L., Wallace A., et al. Substrate specificity and inducibility of TACE (tumour necrosis factor alpha-converting enzyme) revisited: the Ala-Val preference, and induced intrinsic activity. Biochem Soc Symp (2003) 39-52
9. Ludwig A., Hundhausen C., Lambert M.H., Broadway N., Andrews R.C., Bickett D.M., et al. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 8 (2005) 161-171
10. Moss M.L., Bomar M., Liu Q., Sage H., Dempsey P., Lenhart P.M., et al. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J Biol Chem 282 (2007) 35712-35721
11. Zhang Y., Hegen M., Xu J., Keith Jr. J.C., Jin G., Du X., et al. Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme. Int Immunopharmacol 4 (2004) 1845-1857
12. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 (1997) 729-733
13. Kieseier B.C., Pischel H., Neuen-Jacob E., Tourtellotte W.W., and Hartung H.P. ADAM-10 and ADAM-17 in the inflamed human CNS. Glia 42 (2003) 398-405
14. Skovronsky D.M., Fath S., Lee V.M., and Milla M.E. Neuronal localization of the TNFalpha converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. J Neurobiol 49 (2001) 40-46
15. Goddard D.R., Bunning R.A., and Woodroofe M.N. Astrocyte and endothelial cell expression of ADAM 17 (TACE) in adult human CNS. Glia 34 (2001) 267-271
16. Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96 (1999) 3922-3927
17. Buxbaum J.D., Liu K.N., Luo Y., Slack J.L., Stocking K.L., Peschon J.J., et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273 (1998) 27765-27767
18. de Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391 (1998) 387-390
19. Hooper N.M., and Turner A.J. The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer's disease. Curr Med Chem 9 (2002) 1107-1119
20. Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., Kojro E., et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113 (2004) 1456-1464
21. Parkin E.T., Watt N.T., Turner A.J., and Hooper NM. Dual mechanisms for shedding of the cellular prion protein. J Biol Chem 279 (2004) 11170-11178
22. Vincent B., Paitel E., Saftig P., Frobert Y., Hartmann D., de Strooper B., et al. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem 276 (2001) 37743-37746
23. Vincent B. ADAM proteases: protective role in Alzheimer's and prion diseases?. Curr Alzheimer Res 1 (2004) 165-174
24. Hattori M., Osterfield M., and Flanagan J.G. Regulated cleavage of a contact-mediated axon repellent. Science 289 (2000) 1360-1365
25. Janes P.W., Saha N., Barton W.A., Kolev M.V., Wimmer-Kleikamp S.H., Nievergall E., et al. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123 (2005) 291-304
26. Litterst C., Georgakopoulos A., Shioi J., Ghersi E., Wisniewski T., Wang R., et al. Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor. J Biol Chem 282 (2007) 16155-16163
27. Brou C., Logeat F., Gupta N., Bessia C., LeBail O., Doedens J.R., et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 5 (2000) 207-216
28. de Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398 (1999) 518-522
29. Okamoto I., Kawano Y., Murakami D., Sasayama T., Araki N., Miki T., et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 155 (2001) 755-762
30. Marambaud P., Shioi J., Serban G., Georgakopoulos A., Sarner S., Nagy V., et al. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 21 (2002) 1948-1956
31. Maretzky T., Reiss K., Ludwig A., Buchholz J., Scholz F., Proksch E., et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA 102 (2005) 9182-9187
32. Marambaud P., Wen P.H., Dutt A., Shioi J., Takashima A., Siman R., et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 114 (2003) 635-645
33. Reiss K., Maretzky T., Ludwig A., Tousseyn T., de Strooper B., Hartmann D., et al. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J 24 (2005) 742-752
34. Maretzky T., Schulte M., Ludwig A., Rose-John S., Blobel C., Hartmann D., et al. L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol 25 (2005) 9040-9053
35. Shoval I., Ludwig A., and Kalcheim C. Antagonistic roles of full-length N-cadherin and its soluble BMP cleavage product in neural crest delamination. Development 134 (2007) 491-501
36. Reiss K., Maretzky T., Haas I.G., Schulte M., Ludwig A., Frank M., et al. Regulated ADAM10-dependent ectodomain shedding of gamma-protocadherin C3 modulates cell-cell adhesion. J Biol Chem 281 (2006) 21735-21744
37. Kamiguchi H. The mechanism of axon growth: what we have learned from the cell adhesion molecule L1. Mol Neurobiol 28 (2003) 219-228
38. Mechtersheimer S., Gutwein P., Agmon-Levin N., Stoeck A., Oleszewski M., Riedle S., et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 155 (2001) 661-673
39. Stoeck A., Keller S., Riedle S., Sanderson M.P., Runz S., Le N.F., et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J 393 (2006) 609-618
40. Doherty P., Williams E., and Walsh F.S. A soluble chimeric form of the L1 glycoprotein stimulates neurite outgrowth. Neuron 14 (1995) 57-66
41. Roonprapunt C., Huang W., Grill R., Friedlander D., Grumet M., Chen S., et al. Soluble cell adhesion molecule L1-Fc promotes locomotor recovery in rats after spinal cord injury. J Neurotrauma 20 (2003) 871-882
42. Kurz M., Pischel H., Hartung H.P., and Kieseier B.C. Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system. J Peripher Nerv Syst 10 (2005) 311-318
43. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385 (1997) 733-736
44. Moss M.L., White J.M., Lambert M.H., and Andrews R.C. TACE and other ADAM proteases as targets for drug discovery. Drug Discov Today 6 (2001) 417-426
45. Horiuchi K., Kimura T., Miyamoto T., Takaishi H., Okada Y., Toyama Y., et al. Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol 179 (2007) 2686-2689
46. Reddy P., Slack J.L., Davis R., Cerretti D.P., Kozlosky C.J., Blanton R.A., et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 275 (2000) 14608-14614
47. Solomon K.A., Pesti N., Wu G., and Newton R.C. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. J Immunol 163 (1999) 4105-4108
48. Porteu F., and Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172 (1990) 599-607
49. McDermott M.F., Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97 (1999) 133-144
50. Mullberg J., Schooltink H., Stoyan T., Gunther M., Graeve L., Buse G., et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 23 (1993) 473-480
51. Chalaris A., Rabe B., Paliga K., Lange H., Laskay T., Fielding C.A., et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 110 (2007) 1748-1755
52. Matthews V., Schuster B., Schutze S., Bussmeyer I., Ludwig A., Hundhausen C., et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 278 (2003) 38829-38839
53. Althoff K., Reddy P., Voltz N., Rose-John S., and Mullberg J. Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem 267 (2000) 2624-2631
54. Walev I., Vollmer P., Palmer M., Bhakdi S., and Rose-John S. Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. Proc Natl Acad Sci USA 93 (1996) 7882-7887
55. Rose-John S., Scheller J., Elson G., and Jones S.A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80 (2006) 227-236
56. Rabe B., Chalaris A., May U., Waetzig G.H., Seegert D., Williams A.S., et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111 (2008) 1021-1028
57. Badoual C., Bouchaud G., Agueznay N.H., Mortier E., Hans S., Gey A., et al. The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 68 (2008) 3907-3914
58. Budagian V., Bulanova E., Orinska Z., Ludwig A., Rose-John S., Saftig P., et al. Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). J Biol Chem 279 (2004) 40368-40375
59. Bulanova E., Budagian V., Duitman E., Orinska Z., Krause H., Ruckert R., et al. Soluble Interleukin IL-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. J Biol Chem 282 (2007) 13167-13179
60. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76 (1994) 301-314
61. Smalley D.M., and Ley K. L-selectin: mechanisms and physiological significance of ectodomain cleavage. J Cell Mol Med 9 (2005) 255-266
62. Ludwig A., and Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost 97 (2007) 694-703
63. Nagano O., Murakami D., Hartmann D., de Strooper B., Saftig P., Iwatsubo T., et al. Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation. J Cell Biol 165 (2004) 893-902
64. Hafezi-Moghadam A., Thomas K.L., Prorock A.J., Huo Y., and Ley K. L-selectin shedding regulates leukocyte recruitment. J Exp Med 193 (2001) 863-872
65. Hafezi-Moghadam A., and Ley K. Relevance of L-selectin shedding for leukocyte rolling in vivo. J Exp Med 189 (1999) 939-948
66. Venturi G.M., Tu L., Kadono T., Khan A.I., Fujimoto Y., Oshel P., et al. Leukocyte migration is regulated by L-selectin endoproteolytic release. Immunity 19 (2003) 713-724
67. Levesque J.P., Takamatsu Y., Nilsson S.K., Haylock D.N., and Simmons P.J. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 98 (2001) 1289-1297
68. Garton K.J., Gough P.J., Philalay J., Wille P.T., Blobel C.P., Whitehead R.H., et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 278 (2003) 37459-37464
69. Singh R.J., Mason J.C., Lidington E.A., Edwards D.R., Nuttall R.K., Khokha R., et al. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res 67 (2005) 39-49
70. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 385 (1997) 640-644
71. Teupser D., Pavlides S., Tan M., Gutierrez-Ramos J.C., Kolbeck R., and Breslow J.L. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci USA 101 (2004) 17795-17800
72. Damas J.K., Boullier A., Waehre T., Smith C., Sandberg W.J., Green S., et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 25 (2005) 2567-2572
73. Hundhausen C., Schulte A., Schulz B., Andrzejewski M.G., Schwarz N., von Hundelshausen P., et al. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 178 (2007) 8064-8072
74. Hundhausen C., Misztela D., Berkhout T.A., Broadway N., Saftig P., Reiss K., et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102 (2003) 1186-1195
75. Garton K.J., Gough P.J., Blobel C.P., Murphy G., Greaves D.R., Dempsey P.J., et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276 (2001) 37993-38001
76. Tsou C.L., Haskell C.A., and Charo I.F. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem 276 (2001) 44622-44626
77. Ludwig A., Berkhout T., Moores K., Groot P., and Chapman G. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 168 (2002) 604-612
78. Shimaoka T., Nakayama T., Fukumoto N., Kume N., Takahashi S., Yamaguchi J., et al. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol 75 (2004) 267-274
79. Matloubian M., David A., Engel S., Ryan J.E., and Cyster J.G. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 1 (2000) 298-304
80. Shimaoka T., Kume N., Minami M., Hayashida K., Kataoka H., Kita T., et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 275 (2000) 40663-40666
81. Aslanian A.M., and Charo I.F. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 114 (2006) 583-590
82. Sun Y., Chang Z., and Zhang S. Increased serum CXCL16 level is a marker for acute coronary syndromes. Arch Med Res 39 (2008) 332-337
83. Abel S., Hundhausen C., Mentlein R., Schulte A., Berkhout T.A., Broadway N., et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 172 (2004) 6362-6372
84. Gough P.J., Garton K.J., Wille P.T., Rychlewski M., Dempsey P.J., and Raines E.W. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 172 (2004) 3678-3685
85. Weber C., Fraemohs L., and Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol 7 (2007) 467-477
86. Cavusoglu E., Kornecki E., Sobocka M.B., Babinska A., Ehrlich Y.H., Chopra V., et al. Association of plasma levels of F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) with human atherosclerosis. J Am Coll Cardiol 50 (2007) 1768-1776
87. Pruessmeyer J., Koenen R.R., Fraemohs L., et al. Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Wien Klin Wochenschr 120 (2008) 26 [abstract]
88. Ostermann G., Fraemohs L., Baltus T., Schober A., Lietz M., Zernecke A., et al. Involvement of JAM-A in mononuclear cell recruitment on inflamed or atherosclerotic endothelium: inhibition by soluble JAM-A. Arterioscler Thromb Vasc Biol 25 (2005) 729-735
89. Ostermann G., Weber K.S., Zernecke A., Schroder A., and Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol 3 (2002) 151-158
90. Dejana E., Spagnuolo R., and Bazzoni G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thromb Haemost 86 (2001) 308-315
91. Schulz B., Pruessmeyer J., Maretzky T., Ludwig A., Blobel C.P., Saftig P., et al. ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin. Circ Res 102 (2008) 1192-1201
92. Herren B., Levkau B., Raines E.W., and Ross R. Cleavage of beta-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol Biol Cell 9 (1998) 1589-1601
93. Soeki T., Tamura Y., Shinohara H., Sakabe K., Onose Y., and Fukuda N. Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis. Circ J 68 (2004) 1-5
94. Ponnuchamy B., and Khalil R.A. Role of ADAMs in endothelial cell permeability: cadherin shedding and leukocyte rolling. Circ Res 102 (2008) 1139-1142
95. Dejana E., Orsenigo F., and Lampugnani M.G. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 121 (2008) 2115-2122
96. Sanderson M.P., Dempsey P.J., and Dunbar A.J. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors 24 (2006) 121-136
97. Sahin U., Weskamp G., Kelly K., Zhou H.M., Higashiyama S., Peschon J., et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164 (2004) 769-779
98. Sahin U., and Blobel C.P. Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett 581 (2007) 41-44
99. Borrell-Pages M., Rojo F., Albanell J., Baselga J., and Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 22 (2003) 1114-1124
100. Sanderson M.P., Erickson S.N., Gough P.J., Garton K.J., Wille P.T., Raines E.W., et al. ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. J Biol Chem 280 (2005) 1826-1837
101. Gschwind A., Hart S., Fischer O.M., and Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 22 (2003) 2411-2421
102. Hart S., Fischer O.M., and Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64 (2004) 1943-1950
103. Rio C., Buxbaum J.D., Peschon J.J., and Corfas G. Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 275 (2000) 10379-10387
104. Codony-Servat J., Albanell J., Lopez-Talavera J.C., Arribas J., and Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59 (1999) 1196-1201
105. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J., et al. (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61 (2001) 4744-4749
106. Hayes D.F., Yamauchi H., Broadwater G., Cirrincione C.T., Rodrigue S.P., Berry D.A., et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7 (2001) 2703-2711
107. Christianson T.A., Doherty J.K., Lin Y.J., Ramsey E.E., Holmes R., Keenan E.J., et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58 (1998) 5123-5129
108. Liu P.C., Liu X., Li Y., Covington M., Wynn R., Huber R., et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 5 (2006) 657-664
109. Nagano O., and Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 95 (2004) 930-935
110. Cichy J., and Pure E. The liberation of CD44. J Cell Biol 161 (2003) 839-843
111. Okamoto I., Kawano Y., Matsumoto M., Suga M., Kaibuchi K., Ando M., et al. Regulated CD44 cleavage under the control of protein kinase C, calcium influx, and the Rho family of small G proteins. J Biol Chem 274 (1999) 25525-25534
112. Shi M., Dennis K., Peschon J.J., Chandrasekaran R., and Mikecz K. Antibody-induced shedding of CD44 from adherent cells is linked to the assembly of the cytoskeleton. J Immunol 167 (2001) 123-131
113. Okamoto I., Tsuiki H., Kenyon L.C., Godwin A.K., Emlet D.R., Holgado-Madruga M., et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 160 (2002) 441-447
114. Franzmann E.J., Reategui E.P., Pedroso F., Pernas F.G., Karakullukcu B.M., Carraway K.L., et al. Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 16 (2007) 1348-1355
115. Niitsu N., and Iijima K. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma. Leuk Res 26 (2002) 241-248
116. Eisterer W., Bechter O., Soderberg O., Nilsson K., Terol M., Greil R., et al. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res 28 (2004) 1043-1051
117. Okamoto I., Kawano Y., Tsuiki H., Sasaki J., Nakao M., Matsumoto M., et al. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene 18 (1999) 1435-1446
118. Peterson R.M., Yu Q., Stamenkovic I., and Toole B.P. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am J Pathol 156 (2000) 2159-2167
119. Waldhauer I., Goehlsdorf D., Gieseke F., Weinschenk T., Wittenbrink M., Ludwig A., et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 68 (2008) 6368-6376
120. Groh V., Wu J., Yee C., and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002) 734-738
121. Hansen H.P., Dietrich S., Kisseleva T., Mokros T., Mentlein R., Lange H.H., et al. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. J Immunol 165 (2000) 6703-6709
122. Eichenauer D.A., Simhadri V.L., von Strandmann E.P., Ludwig A., Matthews V., Reiners K.S., et al. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro. Cancer Res 67 (2007) 332-338
123. Muraguchi T., Takegami Y., Ohtsuka T., Kitajima S., Chandana E.P., Omura A., et al. RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity. Nat Neurosci 10 (2007) 838-845
124. Endres K., Postina R., Schroeder A., Mueller U., and Fahrenholz F. Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases. FEBS J 272 (2005) 5808-5820
125. Weskamp G., Ford J.W., Sturgill J., Martin S., Docherty A.J., Swendeman S., et al. ADAM10 is a principal 'sheddase' of the low-affinity immunoglobulin E receptor CD23. Nat Immunol 7 (2006) 1293-1298
126. Schulte M., Reiss K., Lettau M., Maretzky T., Ludwig A., Hartmann D., et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ 14 (2007) 1040-1049
127. Rabie T., Strehl A., Ludwig A., and Nieswandt B. Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. J Biol Chem 280 (2005) 14462-14468
128. Budagian V., Bulanova E., Orinska Z., Duitman E., Brandt K., Ludwig A., et al. Soluble Axl is generated by ADAM10-dependent cleavage and associates with Gas6 in mouse serum. Mol Cell Biol 25 (2005) 9324-9339
129. Ahrens I., Ellwanger C., Smith B.K., Bassler N., Chen Y.C., Neudorfer I., et al. Selenium supplementation induces metalloproteinase-dependent L-selectin shedding from monocytes. J Leukoc Biol 83 (2008) 1388-1395
130. Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4 (2007) 412-417
131. Tanaka M., Nanba D., Mori S., Shiba F., Ishiguro H., Yoshino K., et al. ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J Biol Chem 279 (2004) 41950-41959
132. Le Naour F., Andre M., Greco C., Billard M., Sordat B., Emile J.F., et al. Profiling of the tetraspanin web of human colon cancer cells. Mol Cell Proteomics 5 (2006) 845-857
133. Gutwein P., Stoeck A., Riedle S., Gast D., Runz S., Condon T.P., et al. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res 11 (2005) 2492-2501
134. Sugawa M., Ono K., Yasui Y., Kishi T., and Tsumori T. Enhancement of neurite outgrowth by the soluble form of human L1 (neural cell adhesion molecule). Neuroreport 8 (1997) 3157-3162
135. Six E., Ndiaye D., Laabi Y., Brou C., Gupta-Rossi N., Israel A., et al. The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. Proc Natl Acad Sci USA 100 (2003) 7638-7643
136. Rosendahl M.S., Ko S.C., Long D.L., Brewer M.T., Rosenzweig B., Hedl E., et al. Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases. J Biol Chem 272 (1997) 24588-24593
137. Walcheck B., Moore K.L., McEver R.P., and Kishimoto T.K. Neutrophil-neutrophil interactions under hydrodynamic shear stress involve L-selectin and PSGL-1. A mechanism that amplifies initial leukocyte accumulation of P-selectin in vitro. J Clin Invest 98 (1996) 1081-1087
138. Bergmeier W., Piffath C.L., Cheng G., Dole V.S., Zhang Y., von Andrian U.H., et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res 95 (2004) 677-683
139. Contin C., Pitard V., Itai T., Nagata S., Moreau J.F., and Dechanet-Merville J. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J Biol Chem 278 (2003) 32801-32809
140. Horiuchi K., Zhou H.M., Kelly K., Manova K., and Blobel C.P. Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev Biol 283 (2005) 459-471
141. Bech-Serra J.J., Santiago-Josefat B., Esselens C., Saftig P., Baselga J., Arribas J., et al. Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis. Mol Cell Biol 26 (2006) 5086-5095
142. Rosso O., Piazza T., Bongarzone I., Rossello A., Mezzanzanica D., Canevari S., et al. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 5 (2007) 1246-1253
143. McCulloch D.R., Akl P., Samaratunga H., Herington A.C., and Odorico D.M. Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clin Cancer Res 10 (2004) 314-323
144. Gavert N., Sheffer M., Raveh S., Spaderna S., Shtutman M., Brabletz T., et al. Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res 67 (2007) 7703-7712
145. Ko S.Y., Lin S.C., Wong Y.K., Liu C.J., Chang K.W., and Liu T.Y. Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Cancer Lett 245 (2007) 33-43
146. Blanchot-Jossic F., Jarry A., Masson D., Bach-Ngohou K., Paineau J., Denis M.G., et al. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 207 (2005) 156-163
147. Lin H.M., Chatterjee A., Lin Y.H., Anjomshoaa A., Fukuzawa R., McCall J.L., et al. Genome wide expression profiling identifies genes associated with colorectal liver metastasis. Oncol Rep 17 (2007) 1541-1549
148. Roemer A., Schwettmann L., Jung M., Stephan C., Roigas J., Kristiansen G., et al. The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?. J Urol 172 (2004) 2162-2166
149. Ringel J., Jesnowski R., Moniaux N., Luttges J., Ringel J., Choudhury A., et al. Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res 66 (2006) 9045-9053
150. Lendeckel U., Kohl J., Arndt M., Carl-McGrath S., Donat H., and Rocken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 131 (2005) 41-48
151. Wu E., Croucher P.I., and McKie N. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem Biophys Res Commun 235 (1997) 437-442
152. Karan D., Lin F.C., Bryan M., Ringel J., Moniaux N., Lin M.F., et al. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol 23 (2003) 1365-1371
153. Zhou B.B., Peyton M., He B., Liu C., Girard L., Caudler E., et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10 (2006) 39-50
154. Ding X., Yang L.Y., Huang G.W., Wang W., and Lu W.Q. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastroenterol 10 (2004) 2735-2739